Recombinant Human Surv Protein，His

Survivin, a member of the inhibitor of apoptosis protein (IAP) family, has emerged as a crucial player in cancer biology due to its dual role in inhibiting apoptosis and regulating cell division. First identified as a key factor in the regulation of the mitotic spindle during cell division, Surv protein is notably overexpressed in a variety of tumors while being absent in most normal differentiated tissues, making it an attractive target for therapeutic intervention. Research has revealed that Survivin contributes to tumorigenesis by promoting cell proliferation, inhibiting apoptotic processes, and enhancing tumor cell migration and invasion. Its expression correlates with poor prognosis in several cancers, including breast, prostate, and colorectal cancer. Consequently, the development of recombinant Survivin proteins has gained considerable attention within the scientific community, with aims to understand their functional roles and therapeutic potential. Investigating the structure and function of Surv as a recombinant protein can provide insights into its interactions with other cellular molecules and elucidate the mechanisms underlying its anti-apoptotic and cell cycle regulatory functions. Moreover, these studies may foster the development of innovative cancer treatment strategies, such as survivin-targeted therapies and vaccines, to selectively eliminate cancer cells while sparing normal tissues. As a result, the ongoing research into recombinant Survivin proteins holds promise for advancing our understanding of cancer pathology and improving clinical outcomes for patients suffering from malignancies characterized by dysregulated Survivin expression.